Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bevacizumab and Trastuzumab With Paclitaxel on Women With Her2+ Breast Cancer Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer

NCT01321775 is registered in ClinicalTrials.gov with Hospital Universitario Madrid Sanchinarro as lead sponsor.

NCT NCT01321775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01321775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bevacizumab and Trastuzumab With Paclitaxel on Women With Her2+ Breast Cancer Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer
Lead sponsor
Hospital Universitario Madrid Sanchinarro
Phase
Phase 2
Overall status
Unknown status
Start date
August 31, 2009
Completion date
November 30, 2013
Enrollment
44 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer